surpass 2 tirzepatide versus Semaglutide in Type Diabetes (SURPASS-2) | NEJM SURPASS-CVOT: Tirzepatide Significantly Reduces Major

These medications are generally well-tolerated, but the most common side effects include nausea, diarrhea, and sometimes mild indigestion

The gut must bind and escort bile-excreted compounds or they reabsorb and cycle back

Both are injectable peptides administered once weekly

Mounjaro is FDA-approved for managing blood sugar levels in adults with type 2 diabetes mellitus, and Zepbound is indicated for weight loss in patients with obesity and overweight with at least one weight-related health condition (high blood pressure or high cholesterol level) and mild to moderate obstructive sleep apnea

At the time the MDL was formed, at least 30 Ozempic vision-loss claims were consolidated into the federal group lawsuit